NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) —

Eyenovia, Inc.

(NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational products, today announced that Dr. Sean Ianchulev, Chairman, Chief Executive Officer and Chief Medical Officer, will deliver a presentation at Eyecelerator, which is being held on Thursday, April 21 in Washington, DC.

“I am very pleased to have this opportunity to present at this year’s Eyecelerator conference and highlight new data demonstrating the many aspects of our proprietary

Optejet

^®

technology. We believe the

Optejet

^®

coupled with an effective IOP lowering medication may be able to address the shortcomings of existing topical glaucoma medications, potentially improving long-term patient outcomes,” stated Dr. Ianchulev.

Presentation details:

Session:

Company Spotlight Presentations – Glaucoma

Eyenovia:

Changing the Way We Look at Glaucoma

Time:

3:30pm – 4:14pm EDT

About Eyecelerator


Eyecelerator, is a partnership between ASCRS (American Society of Cataract and Refractive Surgery) and the American Academy of Ophthalmology to connect entrepreneurs, investors, businesses and ophthalmologists to accelerate ophthalmic innovation and improve patient outcomes. For more information, visit https://eyecelerator.com.

About ASCRS


ASCRS is an international educational society with ophthalmic surgeons at every career stage. Its mission is to empower anterior segment surgeons to improve the vision, outcomes and quality of life for their patients through innovative approaches to education, advocacy and philanthropy. For more information, visit ascrs.org.

About the American Academy of Ophthalmology


The Academy is the world’s largest association of eye physicians and surgeons. A global community of 32,000 medical doctors, it protects sight and empowers lives by setting the standards for ophthalmic education and advocating for its patients and the public. The Academy innovates to advance the profession and to ensure the delivery of the highest-quality eye care. Through its EyeSmart

^®

articles on AAO.org, the Academy provides the public with the most trusted information about eye health. For more information, visit aao.org.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit Eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Forward-Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.

Eyenovia Contact:


Eyenovia, Inc.

John Gandolfo

Chief Financial Officer



[email protected]

Eyenovia Investor Contact:


Eric Ribner

LifeSci Advisors, LLC



[email protected]



(646) 751-4363

Eyenovia Media Contact:


Eyenovia, Inc.

Norbert Lowe

Vice President, Commercial Operations



[email protected]